Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. (PYRUS)

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Safety and Tolerability,; Pharmacodynamics,; Efficacy,; Metastatic Castrate-Resistant Prostate Cancer (mCRPC),; Tumour Response.; Pharmacokinetics,

Treatments: Drug: Intermittent dosing of AZD5363

Study type: Interventional

Funder types: Industry

Identifiers

NCT01692262

GU86

D3610C00003

Details and patient eligibility

About

To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy, in patients with metastatic Castrate-Resistant Prostate Cancer. AZD5363 will be investigated in patients who have progressed after chemotherapy (Part A) and in patients who have progressed before receiving chemotherapy (Part B).

Recruitment into Part A, Group 1 has been suspended. A new design for this group is currently being evaluated. Part A, group 2 patients (progressed after 1 or more 2nd generational anti-hormonal therapies) will receive AZD5363 480mg bid intermittently (4 days on/3days off).

Part B will only start if there is evidence of anti-tumour activity along with AZD5363 having an acceptable safety profile in Part A. Part B will be conducted in pre-chemotherapy patients on a dose and schedule selected from Part A.

Full description

A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety, Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (PYRUS)

Enrollment: 59 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of informed consent
• Males aged 18 years and older
• Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features for which no standard therapy is currently considered appropriate
• Documented evidence of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
• Part A: Patients must have received prior docetaxel-based chemotherapy for mCRPC and have a Circulating Tumour Cell score of 5;
• Part B: Patients must have progressed before receiving any chemotherapy for mCRPC;

Exclusion criteria

• Any prior exposure to agents which inhibit AKT as the primary pharmacological activity
• Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C, and human immunodeficiency virus
• Spinal cord compression or brain metastases unless asymptomatic, treated, and stable and not requiring steroids
• Clinically significant abnormalities of glucose metabolism
• Major surgery within the previous 4 weeks

Trial design

Primary purpose: Screening

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

59 participants in 3 patient groups

Part A Group 1 Intermittent

Experimental group

Description:

Recruitment suspended and will not be re-opened. See intervention description below.

Treatment:

Drug: Intermittent dosing of AZD5363

Drug: Intermittent dosing of AZD5363

Drug: Intermittent dosing of AZD5363

Part A Group 2 Intermittent

Experimental group

Description:

Recruitment complete. See intervention description below.

Treatment:

Drug: Intermittent dosing of AZD5363

Drug: Intermittent dosing of AZD5363

Drug: Intermittent dosing of AZD5363

Part B

Experimental group

Description:

This part of the study will not be conducted following a review of data from Part A. See intervention description below.

Treatment:

Drug: Intermittent dosing of AZD5363

Drug: Intermittent dosing of AZD5363

Drug: Intermittent dosing of AZD5363